Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2026-05-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
独立董事提名人声明与承诺-雷振华
Board/Management Information Classification · 92% confidence The document is a formal nomination statement and commitment for the independent director candidate (‘雷振华’) by the board of 古汉医药集团股份公司. It outlines board‐level governance and qualification confirmation, but contains no financial data, earnings information, or general regulatory notices. It fits under “Board/Management Information (MANG)” as it announces a board nominee and related declarations.
2026-05-25 Chinese
独立董事提名人声明与承诺-罗怀青
Board/Management Information Classification · 95% confidence The document is a formal nomination statement and undertaking by the company’s board for a candidate to serve as an independent director, detailing qualifications, compliance with regulatory requirements, and board nomination procedures. It does not contain financial statements or report on financial results, nor is it a regulatory announcement about dividend, voting, or capital changes. It clearly pertains to board/management information (appointment/nomination of a director).
2026-05-25 Chinese
古汉医药集团股份公司关于召开2025年度股东会的通知
AGM Information Classification · 89% confidence The document is an official notice by 古汉医药集团股份公司 regarding the convening of its 2025 Annual Shareholders’ Meeting (AGM), including meeting time, venue, agenda items, voting procedures, registration details, and proxy forms. It is neither the meeting minutes nor vote results nor a financial report, but the preparatory materials (meeting notice and related attachments) for the AGM. This matches the definition of “AGM Information” (AGM-R).
2026-05-25 Chinese
独立董事候选人声明与承诺-罗怀青
Regulatory Filings Classification · 95% confidence The document is a standalone declaration and commitment form by an independent director candidate, serving as an attestation/certification of compliance with various laws and regulations. It does not announce an appointment or include substantive financial data. Under the CERTIFICATION RULE, such officer attestations are classified as a general Regulatory Filing.
2026-05-25 Chinese
独立董事候选人声明与承诺-郭东芳
Proxy Solicitation & Information Statement Classification · 85% confidence The document is an official ‘Statement and Commitment’ by an independent director candidate, detailing eligibility, qualifications, and legal compliance for board election. Such candidate statements are part of the proxy solicitation materials sent to shareholders to inform and request votes at a general meeting. Therefore, this fits the Proxy Solicitation & Information Statement category (PSI).
2026-05-25 Chinese
关于控股股东之一致行动人增持公司股份进展暨权益变动触及5%整数倍的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a public equity change announcement by a controlling shareholder’s concerted actor, reporting that their shareholding has increased by 0.07% to reach exactly 25% of total share capital, thereby crossing a 5% threshold and triggering a mandatory disclosure. This fits the definition of “Major Shareholding Notification (Code: MRQ)” rather than a company share buyback (POS) or other categories.
2026-05-18 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.